Thrombin-specific inhibition by and slow cleavage of hirulog-1
- PMID: 1290488
- PMCID: PMC1130947
- DOI: 10.1042/bj2830737
Thrombin-specific inhibition by and slow cleavage of hirulog-1
Abstract
Hirulog-1 [D-Phe-Pro-Arg-Pro-[Gly]4-desulphohirudin-(53-64) (HV1)] was designed to bind by its first four and last 12 residues to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition respectively, with a [Gly]4 bridge and an Arg-Pro bond at the scissional position. Human alpha-, gamma- and zeta-thrombins, as well as bovine trypsin, readily hydrolyse Spectrozyme-TH (D-hexahydrotyrosyl-Ala-Arg p-nitroanilide) at pH 7.4 and approx. 23 degrees C. Both alpha- and zeta-thrombins, which have high fibrinogen-clotting activities (greater than 3000 kunits/g), were inhibited with this substrate by hirulog-1 [Ki = 2.56 +/- 0.35 nM (n = 3) and 1.84 +/- 0.15 nM (n = 3) respectively] and slowly cleaved the inhibitor [k = 0.326 +/- 0.082 min-1 (n = 12) and 0.362 +/- 0.056 min-1 (n = 18) respectively], whereas gamma-thrombin, which has essentially no clotting activity (approx. 4 kunits/g), and trypsin were not inhibited with greater than 1000-fold molar excess of hirulog-1. Similar inhibition parameters were also obtained for hirulog-1 incubated with alpha-thrombin or zeta-thrombin at approx. 23 degrees C and by measuring thrombin activity with fibrinogen in the clotting assay at 37 degrees C. Cleavage of the Arg-3-Pro-4 bond in hirulog-1 by either alpha- or zeta-thrombin was shown by identical cleavage products of either thrombin on h.p.l.c. and by sequence analysis of the alpha-thrombin products. These data demonstrate that hirulog-1 is a specific inhibitor of thrombin forms with high fibrinogen-procoagulant activities and that its Arg-3-Pro-4 bond is slowly cleaved by these thrombin forms.
Comment in
-
Hirulog-1 and -B2 thrombin specificity.Biochem J. 1992 Oct 15;287 ( Pt 2)(Pt 2):663-4. doi: 10.1042/bj2870663. Biochem J. 1992. PMID: 1445227 Free PMC article. No abstract available.
Similar articles
-
Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.Biochem J. 1992 May 1;283 ( Pt 3)(Pt 3):893-7. doi: 10.1042/bj2830893. Biochem J. 1992. PMID: 1590777 Free PMC article.
-
Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.Biochemistry. 1990 Jul 31;29(30):7095-101. doi: 10.1021/bi00482a021. Biochemistry. 1990. PMID: 2223763
-
Thrombin specificity with tripeptide chromogenic substrates: comparison of human and bovine thrombins with and without fibrinogen clotting activities.Clin Chem. 1986 Jun;32(6):934-7. Clin Chem. 1986. PMID: 3708816
-
Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor.Adv Exp Med Biol. 1993;340:227-36. doi: 10.1007/978-1-4899-2418-6_20. Adv Exp Med Biol. 1993. PMID: 8154339 Review. No abstract available.
-
Thrombin inhibition by hirudin: how hirudin inhibits thrombin.Haemostasis. 1991;21 Suppl 1:27-31. doi: 10.1159/000216259. Haemostasis. 1991. PMID: 1894193 Review.
Cited by
-
New anticoagulant drugs.J Thromb Thrombolysis. 2001 Sep;12(1):7-17. doi: 10.1023/a:1013089924994. J Thromb Thrombolysis. 2001. PMID: 11711683 Review.
-
Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors.PLoS One. 2011;6(10):e26367. doi: 10.1371/journal.pone.0026367. Epub 2011 Oct 28. PLoS One. 2011. PMID: 22053189 Free PMC article.
-
High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains.Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6334-8. doi: 10.1073/pnas.91.14.6334. Proc Natl Acad Sci U S A. 1994. PMID: 8022782 Free PMC article.
-
New anticoagulants for the prevention and treatment of venous thromboembolism.Vasc Health Risk Manag. 2005;1(1):41-53. doi: 10.2147/vhrm.1.1.41.58936. Vasc Health Risk Manag. 2005. PMID: 17319097 Free PMC article. Review.
-
Bivalirudin as a bridge for anticoagulation in high risk neurosurgical patients with active DVT or high risk of thrombosis.Neurocrit Care. 2013 Jun;18(3):349-53. doi: 10.1007/s12028-013-9835-0. Neurocrit Care. 2013. PMID: 23568093
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous